Furthermore, the pan-cancer analysis demonstrated significant overexpression of IGF2BP3 in most cancer types (Fig. S1A), indicating its potential as a promising therapeutic target not only for glioma but also for other solid tumors. The gene discussed is IGF2BP3; the disease is glioma.